Is Altimmune a Buy?
Maverick biotech Altimmune (NASDAQ: ALT) has been one of the past year's top growth stocks. In fact, if you'd invested in the company last March, during the beginning of the coronavirus pandemic, that investment would be up more than fivefold. Over the same time, the industry benchmark iShares NASDAQ Biotechnology ETF (NASDAQ: IBB) would have only returned 67%.
Many investors are now wondering if history will repeat itself, and if they could get rich off the stock in a short amount of time should they buy now. I would heavily caution against doing that. If existing shareholders haven't taken profits already, now is the best time to do so in anticipation of what's to come.
Image source: Getty Images.
Source Fool.com
